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ABSTRACT
Purpose: Data from epidemiological and experimental studies suggest that
dietary protein intake may play a role in inhibiting prostate and breast cancer by
modulating the IGF/AKT/mTOR pathway. In this study we investigated the effects of
diets with different protein content or quality on prostate and breast cancer.
Experimental Design: To test our hypothesis we assessed the inhibitory effect
of protein diet restriction on prostate and breast cancer growth, serum PSA and IGF1 concentrations, mTOR activity and epigenetic markers, by using human xenograft
cancer models.
Results: Our results showed a 70% inhibition of tumor growth in the castrateresistant LuCaP23.1 prostate cancer model and a 56% inhibition in the WHIM16 breast
cancer model fed with a 7% protein diet when compared to an isocaloric 21% protein
diet. Inhibition of tumor growth correlated, in the LuCaP23.1 model, with decreased
serum PSA and IGF-1 levels, down-regulation of mTORC1 activity, decreased cell
proliferation as indicated by Ki67 staining, and reduction in epigenetic markers of
prostate cancer progression, including the histone methyltransferase EZH2 and the
associated histone mark H3K27me3. In addition, we observed that modifications of
dietary protein quality, independently of protein quantity, decreased tumor growth.
A diet containing 20% plant protein inhibited tumor weight by 37% as compared to
a 20% animal dairy protein diet.
Conclusions: Our findings suggest that a reduction in dietary protein intake is
highly effective in inhibiting tumor growth in human xenograft prostate and breast
cancer models, possibly through the inhibition of the IGF/AKT/mTOR pathway and
epigenetic modifications.
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INTRODUCTION

animal model of PCa and BC, we first designed and
tested murine diets containing the lowest concentrations
of protein that did not result in weight loss or health
impairment. These studies showed that an “ad libitum”
fed diet providing 7% calories from protein provided the
lowest protein level compatible with health and weight
maintenance (data not shown). In our first experiment
(pre-implantation study), we acclimatized 4-6 week old
male SCID mice to either the 21% or 7% protein diet for
4 weeks, prior to surgical castration and subcutaneous
implantation of LuCaP23.1-CR tumors. As shown in
figure 1A, LuCap23.1-CR xenograft growth was strikingly
reduced in the 7% than in the 20% protein diet group,
resulting in a 70% (p< 0.001, 95% CI= 55.98 to 139.7)
reduced tumor size at 5 weeks post tumor implantation.
Consistently, average tumor weight at the end of the
experiment was 81% (p<0.0009, 95% CI =0.3814-1.243)
lower in the 7% protein than in the 20% protein diet group
(Fig. 1B). In a second experiment (post-implantation
study), protein restriction was initiated in castrated
mice 4 weeks after tumor establishment (~50 mm2). As
shown in figure 1E, also in this setting the 7% protein
diet markedly inhibited tumor growth and resulted in a
~50% (p<0.0275, 95% CI = 0.04232-0.5910) reduction
in tumor weight (Fig.1F). Throughout the 4-month study,
there was no significant difference in mean body weights
between the 7% and the 21% protein diet groups (Fig. 1C).
Interestingly, despite the higher carbohydrate content of
the 7% protein diet, there was no significant difference
in serum glucose concentration between the two groups
(Fig. 1D).
To test the hypothesis whether an isocaloric decrease
in dietary protein intake inhibits tumor growth in a human
animal model of BC as well, we acclimatized 4-6 week old
female NOD-SCID mice to either the 21% or 7% protein
diet for 4 weeks, prior to subcutaneous implantation of
WHIM16 tumor cells. As shown in figure 1G, WHIM16
xenograft growth was significantly reduced in the 7%
as compared to the 20% protein diet group, resulting in
a 56% (p< 0.0232, 95% CI= -153.9 to -12.86) reduced
tumor size. No significant difference in mean body
weights between the 7% and the 21% protein diet groups
was observed (Fig. 1H).

Prostate (PCa) and breast (BC) cancers are the most
commonly diagnosed cancer in men and women living in
Western countries [1]. Studies of populations migrating
from low- to high-risk areas have shown a steep rise in
PCa and BC rate [2,3]. In addition, in the last three decades
the age-standardized PCa and BC incidence and mortality
rate has increased dramatically in Japan and Singapore,
two developed countries previously considered having
a very low prevalence rate [4,5]. These studies strongly
suggest that environmental factors play a key role in PCa
and BC pathogenesis. It has been hypothesized that this
increased prevalence of PCa and BC is partially due to
the radical dietary shifts from traditional to Western diet
patterns [2,6], which are characterized by high intakes of
animal protein and fats, and refined carbohydrates.
Data from epidemiological and experimental studies
indicate that protein intake is one of the most important
dietary regulators of circulating levels of IGF-1, a powerful
growth factor, which activates the Akt/mTOR pathway
[7,8]. High circulating levels of IGF-1 are associated with
increased risk of PCa and BC [9-11], Moreover, multiple
lines of evidence have shown that activation of the PI3K/
AKT/mTOR pathway, through insulin/IGF-1 stimulation
and/or high levels of essential amino acids, play a crucial
role in maintaining the malignant phenotype, and its
inhibition antagonizes growth and motility of a range of
cancer cells in mouse models [12-17].
In this study, we assessed whether a reduction of
protein intake or modifications in aminoacid composition
of isocaloric diets could inhibit PCa growth by using
the LuCaP23.1 androgen-sensitive and castrate-resistant
patient-derived xenograft model. LuCaP23.1 represents
a relevant model for studying therapeutic interventions
in a preclinical setting because it retains major clinical
hallmarks of human PCa, including heterogeneous growth,
prostate specific antigen (PSA) production, androgenresponsiveness, and resistance to castration [18]. In
addition, we assessed whether or not protein intake could
also inhibit BC growth by using the breast cancer cell line
WHIM16. Finally, we investigated whether these dietary
manipulations could modulate IGF-1 production, mTOR
activity, cell proliferation, and key epigenetic markers of
PCa progression, such as the methyltransferase EZH2 and
associated histone mark H3K27me3 [19,20].

Protein restriction reduces serum IGF-1
concentration and attenuates mTOR activity in a
human castrate-resistant, prostate cancer model.

RESULTS

To determine whether dietary protein intake affects
circulating IGF-1 levels in castrated tumor bearing mice,
serum IGF-1 concentration were measured in the two
groups. Serum IGF-1 concentration was significantly lower
in the 7% than in the 21% protein diet group (Fig. 2A). As
both serum IGF-1 and amino acids levels are important
regulators of mTORC1 activity, we were interested in

Protein restriction inhibits tumor growth in
human prostate and breast cancer models.
To test the hypothesis whether a isocaloric decrease
in dietary protein intake inhibits tumor growth in a human
www.impactjournals.com/oncotarget

2452

Oncotarget 2013; 4:

determining whether or not a reduction in protein intake
down-regulates the mTOR signaling pathway in the
LuCaP23.1-CR model, and whether or not the diet-induced
inhibitory effect on tumor growth was dependent on
mTOR inhibition. To test this hypothesis, we assessed the
effects on tumor growth and the levels of phosphorylated
mTOR and p70 S6K in mice treated with diet alone versus
diet in combination with everolimus treatment. As shown
in figure 2B and C, everolimus treatment was as effective
as protein restriction in inhibiting tumor growth and had
greater effect in combination with protein restriction as
compared to lower protein diet alone. Tumor weights
from the animals treated with everolimus alone or the 7%
A

protein diet alone were similar (Fig. 2D). However, tumor
weights were significantly smaller in animals treated with
everolimus fed the 7% protein diet than in those treated
with everolimus fed the 20% protein diet, suggesting that
protein restriction and mTOR inhibition have additive
inhibitory effects on PCa development. Endpoint PSA
measurements confirmed the inhibitory effect of protein
restriction alone and everolimus in both the 21% and 7%
protein diet groups (Fig. 2E). Immunohistochemistry
staining showed a significant decrease in phosphomTORC1 levels following protein restriction (21% protein
diet =37% +/- 2.09 vs. 7% protein diet=19% +/- 2.03,
p<0.0001, 95% CI = 14.51- 26.19), which was even more
E

Pre-implantation Study

Post-implantation Study

*
*
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C

Pre-implantation Study

F
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Figure 1: Low protein diet attenuates the growth of prostate and breast cancer in the castrate-resistant LuCaP23.1
model and in the WHIM16 model, respectively. Tumor sizes were assessed two times a week by caliper measurements. (A, B)

LuCaP23.1-CR and (G) WHIM16 growth curve of tumors already exposed to low protein diet (pre-implantation studies) and endpoint
tumor weights. (E, F) LuCap23.1-CR growth curve of tumors exposed to low protein diet after tumors were implanted and established
(post-implantation studies), and endpoint tumor weights. (C) LuCaP23.1-CR and (H) WHIM16 mouse body weights. (D) Measurements of
serum glucose in LuCaP23.1-CR bearing mice. Results are expressed as the mean +/- SE, n= 7-10; * p<0.05.
www.impactjournals.com/oncotarget
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Figure 2: Low protein diet decreases IGF-1 serum levels and inhibit LuCaP23.1-CR growth in combination with
everolimus. (A) Measurements of serum IGF-1 in LuCaP23.1-CR bearing animals fed with either 21% or 7% protein diet. (B, C) Mice
were acclimatized for four weeks to either 21% or 7% protein diet and after LuCaP23.1-CR xenograft implantation were treated with
everolimus (2 mg/kg PO, daily X5 times/week). (D, E) Endpoint PSA and tumor weights were collected. Results are expressed as the mean
+/- SE, n=10.
p-S6K

p-mTORC1

7% Protein Diet 21% Protein Diet

A

Diet alone

Diet +
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Diet alone

Ki67
Diet +
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Diet alone

Diet +
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B

Figure 3: Low protein diet decreases mTOR and proliferation activity in the LuCaP23.1-CR model. (A) At the end of

the “pre-implantation” experiment, tumor samples were collected and processed. Paraffin embedded tissue specimens were stained for
p-mTOR, p-S6 ribosomal protein and proliferation marker Ki67. (B) Quantification of staining. Results are based on four fields per tissue
and are expressed as the mean +/- SE. **p<0.01 and ***p<0.001.
www.impactjournals.com/oncotarget
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H3K27me3
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Figure 4: Epigenetic alterations associated with low protein diet in the LuCaP23.1-CR model. (A) At the end of the “pre-

implantation” experiment, tumor samples were collected and processed. Paraffin embedded tissue specimens were stained for the histone
methyltransferase EZH2 and the associated histone mark H3K27me3. (B) Quantification of staining. Results are based on four randomly
selected fields and are expressed as the mean + SE. **p<0.01, ***p<0.001

Figure 5: Effect of the different sources of protein diet
on tumor growth and potential molecular mechanisms.
Endpoint LuCaP23.1-CR tumor weights of mice fed with either
21% protein diet (which consist of both plant and animal protein
sources), 20% or 10% protein diet (plant based) or 20% or 10%
protein diet (animal based). Results are presented as a mean +/SE, n= 7-8 per group. *p<0.05, ns= not statistically significant.
www.impactjournals.com/oncotarget

Figure 6: Representative schema of the potential
molecular mechanisms responsible for the biological
effects of protein restriction.
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pronounced when protein restriction was combined with
everolimus (Fig. 3A and B). We also observed a similar
significant decrease in ribosomal protein TOR activity
as indicated by the down-regulation of p70 S6K (21%
protein diet =29%+/- 2.74 vs. 7% protein diet = 8%+/0.84, p<0.0001, 95% CI= 15.4- 27.34) in mice fed the 7%
protein diet, which is potentiated by everolimus treatment.
Interestingly, associated with the reduced mTOR activity
we observed a decreased number of proliferating cells as
indicated by the Ki67 staining (21% protein diet = 47%
+/- 4.5 vs. 7% protein diet = 22% +/- 3.4, p<0.0041, 95%
CI= 11.55- 39.10) (Fig. 3A and B). Protein diet restriction
induced a similar inhibition of mTOR pathway and Ki67
expression in another patient-derived xenograft model of
PCa (supplementary Fig. S1).

delaying PCa growth, mice were placed on either regular
(20%) or a reduced (10%) protein diet from animal
or vegetable sources for 4-weeks prior to surgically
castration and subcutaneous implantation of LuCaP23.1CR xenografts. At the end of the experiment (6 weeks),
mice were sacrificed and tumor weights were collected.
As shown in figure 5, a diet containing 20% plant protein
decreased tumor weight by 37% as compared to a 20%
animal dairy protein diet (p<0.045, 95% CI= -1.484 to
-0.01818). The inhibitory effect on tumor growth exerted
by the 20% and 10% plant protein diets was similar.
Interestingly, there was no additive effect of switching
from animal to plant proteins when dietary protein content
was 10%, suggesting that a threshold exists below which
the amino acid composition is less important than the
protein content of the diet.

Protein restriction inhibits tumor growth in a
human androgen-sensitive prostate cancer model.

DISCUSSION
In this study we examined the effects of isocaloric
modifications in dietary protein quantity or quality on
tumor growth in the human xenograft LuCaP23.1 (CR
and AS), LuCaP35V (CR) and WHIM16 BC models. Our
findings indicate that dietary protein reduction results in a
marked inhibition of PCa and BC growth. This inhibitory
effect was associated with a reduction in serum PSA
and IGF-1 levels, and a down-regulation of intratumor
mTOR activity in the LuCaP23.1 LuCaP35V models.
Protein restriction was also associated with modulation
of specific histone markers suggesting epigenetic
modulation. Interestingly, the source of proteins appears
to be important, as tumor inhibition was also achieved
by changes in the quality (i.e. aminoacid composition of
vegetable versus dairy) of protein food.
Accumulating scientific data indicate that
perturbations in the IGF/PI3K/Akt/mTOR pathway
play a key role in the pathogenesis of PCa and BC [1018,24]. A linear relationship exists between circulating
IGF-1 levels and the risk of developing PCa and BC
[9,10,24], and the PI3K/Akt/mTOR signaling pathways
is upregulated in 30-50% of PCa [12,13]. Data from
epidemiological and human experimental studies suggest
that dietary protein or essential amino acid restriction is
more powerful than calorie or fat restriction in lowering
the circulating levels of IGF-1, which in turn inhibits the
PI3K/AKT/mTOR pathway [7,8,21,23,24]. Consistently,
our data show that an isocaloric reduction of protein
intake significantly reduces serum IGF-1 concentrations,
inhibits mTOR activity, as indicated by a down-regulation
of phosphorylated mTOR and p70-S6K, and reduces cell
proliferation as indicated by the decrease in Ki67. In
addition, our data show that a reduction of diet protein
intake from 21% to 7% inhibits PCa and BC growth
by 70% or more both when tumors where implanted 4
weeks before (pre-implantation studies) or 4 weeks after
(post-implantation studies) the implementation of protein

To determine whether the androgen status could
affect the inhibitory effects of protein restriction on
PCa growth, we acclimatized the mice to either 21%
or 7% protein diet and after four weeks we inoculated
LuCaP23.1-AS tumors orthotopically in the prostate
of non-castrated SCID mice. The 7% protein diet had a
dramatic inhibitory effect on the growth of AS tumors
implanted orthotopically in the prostate of intact animals
(supplementary Fig. S2). Interestingly, the effects of
protein restriction on average tumor weight was identical
in the animal fed with a 7% diet alone and in those fed a
21% protein diet treated with everolimus.

Protein
restriction
modifications.

induces

epigenetic

Because in our study the tumor inhibitory effects of
protein restriction were partially independent of mTOR,
we assessed whether epigenetic modifications, that are
known to be associated with PCa progression, were
modified by protein restriction in the LuCaP23.1-CR
model. We found that the mice fed with a 7% protein diet
had significantly lower expression of EZH2 (21% protein
diet = 97.3% +/- 4.4 vs. 7% protein diet = 55.1% +/- 3.46,
p<0.0001, 95% CI= 32.8- 51.65) and H3K27me3 (21%
protein diet =82.3% +/- 4.4 vs. 7% protein diet= 54.9%
+/- 3.8, p<0.0051, 95% CI= 11.83- 43.02) (Fig. 4A, B and
C). Similar changes in EZH2 and H3K27me3 were also
observed in mice treated with everolimus.

Plant protein diets inhibit tumor growth
independently of protein content.
To investigate whether modifications in protein
quality (i.e. aminoacid composition) are beneficial in
www.impactjournals.com/oncotarget
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restriction. This inhibition in PCa growth induced by
protein restriction appears to be greater than the effect
induced by fat or carbohydrate restriction previously
reported by other groups [25-27], and similar to the
inhibitory effect induced by calorie restriction [28]. We
also observed an additive effect of protein restriction
and pharmacological mTOR inhibition (i.e. everolimus
treatment) on mTOR activity, cell proliferation and PCa
growth, suggesting that protein restriction works through
multiple pathways and molecular targets. Interestingly,
LuCaP23.1 is a PTEN expressing tumor, but with intrinsic
mTOR pathway activation. Ongoing studies with PCa
derived from genetically modified mice will determine the
importance of mTOR activity in the sensitivity to protein
restriction.
At least 15-17% (i.e. ~1.3-1.5 g/kg/body weight)
of the total calories consumed by US and Northern
European citizens comes from dietary protein, which is
two-fold higher than what is recommended by the USDA
(i.e. recommended daily allowance, 0.85 g/kg/body
weight or 10% protein from calories) and of the quantity
consumed (9% calorie from protein) by the Okinawan
centenarians who had one of the lowest rate of PCa and
BC in the world [29-32]. Moreover, the great majority of
proteins in the typical Western diet come from meat, egg
and dairy food sources, which are very rich in essential
amino acids. Elevated levels of essential amino acids
are able to fully activate, independently of IGF-1-insulin
signaling, the TORC1 complex, which regulates cell
growth, protein synthesis, and autophagy [12]. Our data
suggest that feeding mice isocaloric and isoproteic diets
with lower concentrations of some essential aminoacids
(i.e. isoleucine, lysine, tyrosine, threonine, tryptophan,
valine and methionine) reduces PCa growth, though at
a lesser extent than protein restriction. Our experimental
findings support the notion that the high intake of animal
(dairy) proteins in Western diets may play a role in PCa
development and progression, whereas more traditional
diets rich in proteins from cereals and legumes might
partially inhibit PCa growth [33].
Epigenetics is a potential mechanistic link between
diet, energy metabolism, and gene expression modulation
[34,35]. Highly accessible chromatin or open chromatin
is typically observed at active regulatory regions like
enhancers and promoters. Closed chromatin, on the other
hand, is observed at silenced regions like hyper-methylated
promoters of repressed genes. Diet and energy metabolism
affect epigenetic enzymes that regulate histone marks [3436]. Enhancer of zeste homolog 2 (EZH2), a subunit of
Polycomb repressive complex 2, inhibits gene expression
via its histone methyltransferase activity. A recent
report has shown that the oncogenic function of EZH2
in cells of CR prostate cancer is independent of its role
as a transcriptional repressor and involves its the ability
to act as a coactivator for critical transcription factors
including the androgen receptor [16]. Interestingly, in our
www.impactjournals.com/oncotarget

study we observed that protein restriction decreased the
expression of EZH2 and its associated histone repressive
marker H3K37me3. This observation suggests that protein
restriction is responsible for selective epigenetic changes
that may drive modulation specific pathways involved
in PCa growth and survival (Fig. 6). Additional studies
are needed to shed light on the specificity of the histone
markers and associated gene expression modulation
following protein restriction.
The results from our studies may have a rapid
translation into the clinic. We envision that patients with
recurrent PCa and BC could be offered diet modifications
involving protein dietary content at different stages of
their disease with appropriate monitoring. The absence
of a differential effect in the AS and CR LuCaP23.1
models suggest that the androgen status does not affect
the response of PCa to protein restriction. Furthermore,
intratumor androgen receptor expression was not inhibited
in the 7% protein diet group (data not shown). An ongoing
clinical study in patients with newly diagnosed PCa will
provide important information on the biological changes
following this dietary intervention before prostatectomy.
In summary, a high-protein diet promoted the growth
of human LuCaP23.1 and WHIM16 tumors in mice, and
a reduction in protein intake resulted in a significant
inhibition of tumor growth even when the diet was
started after the formation of measurable tumors, possibly
through inhibition of the IGF/Akt/mTOR pathway and
epigenetic modifications. Moreover, our findings indicate
that plant proteins partially inhibit prostate cancer growth
independently of caloric or proteic intake, suggesting
that protein quality plays a key role in the progression
of prostate and breast cancer. Clinical studies in patients
with prostate and breast cancer are warranted to confirm
the impact of dietary modifications in protein content and
quality on tumor progression.

MATERIALS AND METHODS
Androgen-sensitive
and
castrate-resistant
LuCaP23.1 xenograft models of human prostate
cancer.
Six-weeks old, male homozygous Icr SCID mice
were purchased from the in-house animal resource
core facility Roswell Park Cancer Institute (Buffalo,
NY). Mice were housed and maintained in a sterile and
pathogen free facility, in accordance with the Institutional
guidelines credited by the Institutional Animal Care and
Use Committee. Castrate-resistant (CR) LuCaP23.1
xenografts were generated by serial passages of androgensensitive (AS) LuCaP23.1 tumors in surgically-castrated
mice [18]. LuCaP23.1 AS and CR tumors were dissected
into ~1 mm2 pieces and implanted either subcutaneously
2457
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Table 1: Composition and ingredients of experimental diets
21%
mix
protein
Diet composition
Total energy value
(kcal/g)
Carbohydrate (%Kcal)
Fat (%kcal)
Protein (%Kcal)
Leucine (g/kg)

7%
mix
protein

20%
10%
plant
plant
protein protein
Diet composition
Total energy value
(kcal/g)
Carbohydrate (%Kcal)
Fat (%kcal)
Protein (%Kcal)
Leucine (g/kg)

63.6
16.4
20.0
18.7

74.0
16.0
10.0
9.4

73.0
20.2
6.8
8.8

Isoleucine (g/kg)

7.8

2.7

Isoleucine (g/kg) 7.9

4.0

Isoleucine (g/kg)

10.1

5.0

Lysine (g/kg)

16.3

4.0

Lysine (g/kg)

3.9

1.9

Lysine (g/kg)

15.7

7.9

Methionine (g/kg) 6.7

1.9

Methionine (g/kg) 4.1

2.1

Methionine (g/kg) 4.9

2.4

Cysteine (g/kg)

7.2

3

Cysteine (g/kg)

3.0

1.5

Cysteine (g/kg)

2.0

1.0

Arginine (g/kg)

6.3

2.9

Arginine (g/kg)

7.8

3.9

Arginine (g/kg)

6.7

3.3

Phenylalanine (g/kg) 6.6

2.4

Phenylalanine (g/kg) 8.8

4.4

Histidine (g/kg)

3.4

Threonine (g/kg)

9.7

73.5
16.6
10.0
10.6

3.7

58.9
20.1
20.9
25.4

2.4

62.4
17.6
20.0
21.2

3.7

3.6

6.9

3.7

10%
dairy
protein

3.6

Tyrosine (g/kg)

3.7

Diet composition
Total energy value
(kcal/g)
Carbohydrate (%Kcal)
Fat (%kcal)
Protein (%Kcal)
Leucine (g/kg)

20%
dairy
protein

Phenylalanine (g/kg) 10.4

5.2

Tyrosine (g/kg)

5.0

2.5

1.4

Histidine (g/kg)

4.2

3.3

Threonine (g/kg) 5.5

Tryptophan (g/kg) 3.4

1.0

Valine (g/kg)

8.4

3.2

Formula (g/kg)
Corn
Lactalbumin
DL-Methionine
Corn starch

430
177
2.0
149

430
35
0.4
287.4

Maltodextrin

100

100

Corn oil
29
Olive oil
29
Cellulose
30
* Mineral Mix, AIN35
93G-MX
Calcium phosphate

8

***Vitamin Mix,
10
Tekland

32
32
30
35
8
10

Tyrosine (g/kg)

9.2

4.6

2.1

Histidine (g/kg)

4.9

2.4

2.7

Threonine (g/kg)

8.4

4.2

Tryptophan (g/kg) 1.6

0.8

Tryptophan (g/kg) 2.5

1.2

Valine (g/kg)

8.7

4.3

Valine (g/kg)

11.8

5.9

110
136
22
325.4
100
150
32
32
50

55
68
11
459
100
150
32
32
50

170
44

85
22

380.1
100
150
32
32
50

486.3
100
150
32
32
50

13.4

13.4

13.4

13.4

12
7.0

12.6
6.8

8
10.3

10.8
8.3

10

10

10

10

Formula (g/kg)
Wheat gluten
Corn gluten (60%)
Isolated soy protein
Corn starch
Maltodextrin
Sucrose
Corn oil
Olive oil
Cellulose
** Mineral Mix, w/o Ca
&P
Calcium phosphate
Calcium carbonate
***Vitamin Mix,
Teklad

Formula (g/kg)
Casein
Lactalbumin
Corn starch
Maltodextrin
Sucrose
Corn oil
Olive oil
Cellulose
**Mineral Mix, w/o Ca
&P
Calcium phosphate
Calcium carbonate
***Vitamin Mix,
Teklad

*Mineral Mix, AIN-93G-MX (No. 94046), **Mineral Mix, w/o Ca & P (No. 98057), *** Vitamin Mix, Teklad (40060),

WHIM16 xenograft model of human breast
cancer.

under the skin or orthotopically into the dorsal lobe of
the prostate in both intact (LuCaP23.1-AS) or surgicallycastrated (LuCaP23.1-CR) mice. Similar approach was
used for LuCaP35V-CR. All mice were operated under
sedation with oxygen, isoflurane and buprenorphine.
Mice were randomly grouped and placed on either 21%
or 7% protein diets prior to tumor implantation (n=16-20
per group) or after tumor implantation (n=7 per group) or
placed on diets from different sources of protein (n= 7-8
per group).
www.impactjournals.com/oncotarget

Six-weeks old, female NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ mice were purchased from the Jackson
Labs. Mice were housed and maintained in a sterile and
pathogen free facility. WHIM16 tumor cell line was
generated from a patient with ER positive/PR negative/
HER2 negative breast cancer (Washington University).
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This tumor cell line carries also a PI3K mutation with
activation of the AKT/mTOR pathway (manuscript
submitted). Five million WHIM16 cells were implanted
subcutaneously under the skin. All mice were operated
under sedation with oxygen, isoflurane and buprenorphine.
Mice were randomly grouped and placed on either 21%
or 7% protein diets prior to tumor implantation (n=10 per
group).

endogenous activity. To examine the expressions of our
proteins of interests, tissue section were blocked with
2.5% horse serum (Vector Laboratories) and incubated
overnight in primary antibodies against p-mTOR (1:400,
Cell Signaling), p-S6K (1:200, Cell Signaling), Ki67
(1:50, Thermo Fisher), EZH2 (1:50, Cell Signaling), and
H3k27me3 (1:200 Cell Signaling). Following primary
incubation, tissue sections were incubated in horseradishconjugated anti-rabbit or anti-mouse antibody according to
manufacturer’s protocol (Vector Laboratories) followed by
enzymatic development in diaminobenzidine (DAB) and
counter stained in hemotoxyline. Section were dehydrated
and mounted with cytoseal 60 (Thermo Scientific).
Stained sections were analyzed under bright field using
the Zeiss Axio microscope. The number of positive cells
was determined in a blinded fashion by analyzing four
random 20x fields per tissue and quantified using Image
J software.

Feeding protocol and drug treatment.
The six experimental diets were prepared and
sterilized by irradiation by Harlan Laboratories (Madison,
WI). A summary of the composition and ingredients of
each diet are shown in table 1. Animals were allowed free
access to food in cage and autoclaved water supply via
auto-watering system. Male mice that were randomized
into 21% protein diet and 7% protein diet were further
randomized within each group to either receive treatment
with everolimus (10 mg/kg, 5 days on/2 days off) or
vehicle.

Statistical analysis.
Quantitative measures were compared between
groups (normal diet versus low protein or modified diets,
with or without treatment) using two-tailed Student’s t-test
calculated by Graph-Pad software. The P values < 0.05
were considered to be statistically significant. The data are
presented as mean ± SE.

Tumor assessment.
For tumors implanted subcutaneously, tumor sizes
and body weights were recorded twice and once a week,
respectively. Tumor weights were measured by using a
weighing scale at the end of the experiments. Tumor sizes
were assessed by caliper measurements of two diameters
of the tumor (longest length x shortest length = mm2).
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At the end of the experiment, blood was drawn
from all mice by cardiac bleed. Serum was separated,
and aliquots were either used to assess levels of PSA and
glucose in the serum or stored in -800C for further analysis.
Serum insulin growth factor 1 (IGF-1) concentration
was measured in duplicates (n=8 per diet group) using
a mouse specific IGF-1 ELISA kit (Abcam, Cambridge,
MA, USA). Tumor tissues were excised, weighed and
either stored in -800C or fixed in 10% buffered formalin
for histopathology.
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